A. H. Patel

The paper assesses the virulence of the SARS-CoV-2 BA.2.86 variant in hamsters and finds it is attenuated compared to BA.2.75.

This paper shows the P681H mutation in the SARS-CoV-2 alpha variant's Spike protein enables resistance to type I interferon and IFITM proteins, enhancing viral entry and transmission.

This study validates a ZIKV vaccine candidate by testing its efficacy in a mosquito-mouse transmission model, showing protection against disease and reduced viral transmission.

This study shows that later Omicron subvariants of SARS-CoV-2, such as BA.4 and BA.5, have evolved enhanced innate immune suppression compared to earlier subvariants like BA.1 and BA.2.

This study identifies ARHGEF3/XPLN as an antiviral gene that inhibits HCV and flavivirus replication in both humans and rhesus macaques through a genome-wide screen.

This paper develops an efficient HCV genotype 1b infectious cell culture model through adaptation, enabling vaccine development and understanding viral evolution post-transplant.

This study identifies distinct genetic determinants in the Omicron spike protein for altered cell entry and antigenic properties, showing they are separable and may affect future variant severity and vaccine efficacy.

This study shows the P681H mutation in the SARS-CoV-2 alpha variant's Spike protein confers resistance to Type I interferon, enhancing viral replication by evading innate immune responses.

The paper identifies spike mutations that adapt SARS-CoV-2 to mustelid hosts and assesses their impact on human infectivity and antigenicity.

This study shows that in vitro evolution of SARS-CoV-2 under remdesivir selects for resistant mutations, but these mutations do not spread widely in global variants.